| Powder: | Yes |
|---|---|
| Customized: | Customized |
| Certification: | GMP, HSE, ISO 9001, USP, BP |
| Suitable for: | Adult |
| State: | Solid |
| Purity: | >99% |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
| Product Name | Sermaglutide |
| Appearance | White or almost white ,crystalline powder. |
| CAS | 910463-68-2 |
| MF | C187H291N45O59 |
| MW | 4113.57754 |
| Assay | 99% |
Semaglutide (USAN; trade name Ozempic) is a pharmaceutical drug in development by a Danish company Novo Nordisk for the treatment of type 2 diabetes. It is marketed by the name Ozempic. It was discovered in 2012, by a team of researchers at Novo Nordisk as a longer-acting alternative to liraglutide. Clinical trials were started in 2015, and phase 3 was completed in 2016. FDA approval was applied in December 2016, and in October 2017 FDA Advisory Committee voted 16-0 in favour. It can be used as both injection-type or oral-type drug.
Researchers at the University of Leeds reported in 2017 that it can also be used for the treatment of obesity. It reduces hunger, food craving and body fat.
1. It can be used as both injection-type or oral-type drug.
2. Researchers at the University of Leeds reported in 2017 that it can also be used for the treatment of obesity.
3.It reduces hunger, food craving and body fat.
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}